Received Oct 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 3 | — | — |
No additional AE reported; their three dose series of GARDASIL 9 earlier than the recommended intervals as follows: FRIST DOSE: 6/8/2025; SECOND DOSE: 7/11/2025; THIRD DOSE: 10/10/2025; This spontaneous report was received from a pharmacist and refers to a 33-year-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 08-Jun-2025, the patient was vaccinated with first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) 0.5 mL (route, lot # and expiration date were not reported) for prophylaxis. On 11-Jul-2025, the patient was vaccinated with second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) 0.5 mL (route, lot # and expiration date were not reported) for prophylaxis. On 10-Oct-2025, the patient was vaccinated with third dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL9) 0.5 mL (route, lot # and expiration date were not reported) for prophylaxis. This dose was administered earlier than the recommended intervals (inappropriate schedule of product administration). No additional adverse event was reported (no adverse event). Lot # is being requested and will be submitted if received.